13 Jul 2010
Well first of the uses of this medication is a synthetic hormone. It is used to treat pain and infertility caused by endometriosis, a condition involving the tissue of the uterus. It is also used in the treatment of cysts or lumps in the breast or may be prescribed for heavy menstrual flow.
By the way this medication is for women.
13 Jul 2010
Danazol (DANOCRINE) is indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females.
Hereditary Angioedema: The dosage requirements for continuous treatment of hereditary angioedema with Danazol (DANOCRINE) should be individualized on the basis of the clinical response of the patient. It is recommended that the patient be started on 200 mg, two or three times a day. After a favorable initial response is obtained in terms of prevention of episodes of edematous attacks, the proper continuing dosage should be determined by decreasing the dosage by 50% or less at intervals of one to three months or longer if frequency of attacks prior to treatment dictates. If an attack occurs, the daily dosage may be increased by up to 200 mg. During the dose adjusting phase, close monitoring of the patient’s response is indicated, particularly if the patient has a history of airway involvement.
However please do confirm for accurate information from your doc/pharmacist who prescribed the med., hope this helps?
- Danazol Information for Consumers
- Danazol Information for Healthcare Professionals (includes dosage details)
- Side Effects of Danazol (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
... ATG-Cyclosporain(Sandimon) -Danazol-Predinazol-G-csf but i dont become good please help me what do i do;
1 answer • 8 Dec 2009
should males avoid sexual activity too while on this drug?
1 answer • 12 Apr 2010
I was taking 600mg Caltrate and 1000IU Vitamin D supplements. Then I heard that is fine for women but not recommended for males, and that it can ...
1 answer • 25 Mar 2013